Market Exclusive

Analyst Downgrades – Cytori Therapeutics (NASDAQ:CYTX) Stock Gets Downgraded By B. Riley from Buy to Neutral

Analyst Ratings For Cytori Therapeutics (NASDAQ:CYTX)

Today, Cytori Therapeutics (NASDAQ:CYTX) stock was downgraded by B. Riley from Buy to Neutral.

There are 1 hold rating, 1 buy rating on the stock.

The current consensus rating on Cytori Therapeutics (NASDAQ:CYTX) is Buy (Score: 2.50) with a consensus target price of $6.15 per share, a potential 1,181.52% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Cytori Therapeutics (NASDAQ:CYTX)
Cytori Therapeutics (NASDAQ:CYTX) has insider ownership of 2.60% and institutional ownership of 8.65%.

Recent Trading Activity for Cytori Therapeutics (NASDAQ:CYTX)
Shares of Cytori Therapeutics closed the previous trading session at 0.480 down -0.630 -56.77% with 7,464,054 shares trading hands.

Exit mobile version